Congress mandates free heart-disease screening for millions—but leaves uninsured behind
H.R. 8260 — Cardiovascular Disease Early Detection and Prevention Act of 2026 · Filed by Sheila Cherfilus-McCormick (D-FL) · Introduced Apr 14, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires Medicare, Medicaid, and private health insurance plans to cover two specific blood tests—lipoprotein (Lp(a)) and apolipoprotein B (ApoB)—without cost-sharing (copays, deductibles) for people at risk of cardiovascular disease, including those with family history, prior heart attack or stroke, diabetes, obesity, or elevated cholesterol. The tests would be available at no out-of-pocket cost to eligible patients starting 180 days after enactment.
Why we flagged it
The bill's core function is to mandate insurance coverage of two specific cardiovascular diagnostic tests without cost-sharing for at-risk populations. It is a public-health-oriented insurance regulation, not a tax measure, subsidy, or commemorative act.
What the text implies
- Lp(a) and ApoB testing are not yet standard-of-care in many clinical settings; mandating coverage may drive rapid adoption and create demand for lab capacity and physician training in interpreting these markers.
- The bill defines eligibility broadly ('other recognized cardiovascular risk factors'), leaving room for clinical interpretation and potential variation in coverage across states and insurers.
The full analysis lists 4 implications of this text.
Who stands to gain
clinical laboratory companies (Quest Diagnostics, LabCorp, Sonic Healthcare); diagnostic test manufacturers (Roche, Abbott, Siemens Healthineers); cardiology practices and primary care providers